Abstract:Abstract Erythropoietin (EPO) is a tissue-protective cytokine that exerts cytoprotective effects against various types of injury in non-hematopoietic tissues. Our previous work using Langendorff-perfused adult rat hearts demonstrated that EPO improves left ventricular function and reduces infarct size during ischemia-reperfusion injury. Recent studies of EPO variants that retain tissue-protective properties of EPO in non-hematopoietic tissues without stimulating erythropoiesis suggested fundamental differences between EPO-mediated cellular signaling in hematopoietic versus non-hematopoietic cells as well as novel clinical applications for recombinant EPO and its derivatives in disorders other than anemia. In this study, we characterized the activation of EPO-mediated intracellular signal transduction in primary cardiac myocytes and determined the specific pathways required for protection of cardiomyocytes against hypoxic injury. We also investigated the ability of EPO to protect against cell death induced by doxorubicin (DOX), a chemotherapeutic agent associated with well-established cardiotoxic effects. We hypothesized that protective effects of EPO during hypoxic or DOX-mediated cardiomyocyte injury may be inhibited by specific kinase inhibitors targeting pathways activated by EPO. Primary cardiac myocytes were isolated from neonatal rat ventricles (NRVM) establishing cultures containing >97% cardiac myocytes as determined by immunostaining of cells with anti-cardiac muscle sarcomeric actinin. We found that EPO induces the rapid phosphorylation of PI3K substrate Akt and p44/42 MAP kinases Erk 1/2 in a time-dependent fashion. Constitutive tyrosine phosphorylation of Jak2 was observed that did not increase following EPO treatment of cardiomyocytes. Pre-incubation of cells with PI3K inhibitor LY294002 or MEK inhibitor U0126 prior to EPO treatment inhibited the increased phosphorylation of Akt and Erk1/2, respectively. EPO treatment of NRVMs significantly reduced hypoxia-induced apoptosis by 44% assessed by immunoflurescence microscopy of cardiomyocytes double-labeled with TUNEL and DAPI to quantify apoptotic nuclei (P<0.001 by ANOVA; hypoxia-treated versus hypoxia+EPO, n=12 fields of ~4,000 cells in each group). The ability of EPO to protect against hypoxia-mediated apoptosis was also confirmed by a cell-death ELISA that quantifies mono- and oligo-nucleosomes associated with apoptosis. Treatment of cells with LY294002 or protein kinase C inhibitor chelerythrine abolished the anti-apoptotic effect of EPO during hypoxia, whereas treatment with U0126 or Jak2 inhibitor AG490 did not. We also found that EPO exerts a significant protective effect during DOX-induced cell death in a dose-dependent manner, reducing apoptosis by 36% in TUNEL assays (P<0.001 by ANOVA; DOX-treated versus DOX+Epo, n= 6 fields of ~2,000 cells in each group) and by 29% in ELISA assays (P<0.001 by ANOVA, DOX-treated versus DOX+Epo, n=14). Treatment of cells with LY294002 abrogated the anti-apoptotic effect of EPO in NVRMs treated with DOX. These findings demonstrate that 1)-EPO induces rapid phosphorylation of Akt and Erk1/2 but not Jak2 in primary cardiac myocytes in a time-dependent fashion; 2)-EPO protects cardiomyocytes against apoptosis induced by hypoxia or DOX; 3)-The protective effect of EPO during hypoxia-mediated injury of cardiomyocytes requires the PI3K and PKC pathways, but not MAP kinase or Jak2 pathways; 4) The protective effect of EPO during DOX treatment of cardiomyocytes requires the PI3K pathway.

Cardiomyocyte crosstalk with endothelium modulates cardiac structure, function, and ischemia-reperfusion injury susceptibility through erythropoietin

Novel roles of cardiac-derived erythropoietin in cardiac development and function

Increased Myocardial Stiffness Activates Cardiac Microvascular Endothelial Cell Via VEGF Paracrine Signaling in Cardiac Hypertrophy

Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart

Erythropoietin signal pathway is upregulated in mesenchymal stem cell during hypoxia

Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling

The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise

Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor

Contribution of VEGF-B-Induced Endocardial Endothelial Cell Lineage in Physiological Versus Pathological Cardiac Hypertrophy

Vascular Endothelial S1pr1 Ameliorates Adverse Cardiac Remodelling Via Stimulating Reparative Macrophage Proliferation after Myocardial Infarction.

Erythropoietin Protects Cardiomyocytes Not Only during Hypoxic Injury but Also Against Doxorubicin-Induced Apoptosis: A Novel Effect Mediated by Phosphatidylinositol 3-Kinase Pathway.

Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats

Neuronal nitric oxide synthase required for erythropoietin modulation of heart function in mice

Erythropoietin Prevents the Acute Myocardial Inflammatory Response Induced by Ischemia/reperfusion Via Induction of AP-1.

The Endothelium-Dependent Effect of RTEF-1 in Pressure Overload Cardiac Hypertrophy: Role of VEGF-B

Erythropoietin Reduces Myocardial Ischemia-Reperfusion Injury in Rats

VEGF/eNOS‐mediated Cardiomyocyte Proliferation: a Novel Mechanism to Regulate Cardiovascular Regeneration in Mice and Humans

Sexually Dimorphic Adaptation of Cardiac Function: Roles of Epoxyeicosatrienoic Acid and Peroxisome Proliferator-Activated Receptors

Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity

Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis

Endothelial estrogen - myocardial cGMP axis critically determines angiogenesis and cardiac performance during pressure-overload